PD-1 inhibitor

Latest news

Tag

Retifanlimab Plus Chemotherapy Significantly Prolongs Survival in Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial

The POD1UM-304 study demonstrated that adding the PD-1 inhibitor retifanlimab to platinum-based chemotherapy significantly improves overall survival in patients with first-line metastatic non-small-cell lung cancer, offering a new therapeut

Oct 15, 2025

Clinical Updates

Butyrate-Producing Clostridium butyricum: A Direct Interactor with Colorectal Cancer Cells that Reverses Immune Suppression and Enhances Checkpoint Inhibitor Efficacy

Recent research uncovers that the probiotic Clostridium butyricum directly interacts with colorectal cancer cells to inhibit immune suppression via the secD-GRP78 axis, restoring CD8+ T cell antitumor function and enhancing PD-1 inhibitor t

Aug 23, 2025

Clinical Updates

Overcoming PD-1 Inhibitor Resistance: Six Emerging Strategies from the 2025 ASCO Annual Meeting

PD-1 inhibitor resistance is a major hurdle in cancer immunotherapy. Six leading combination strategies—including chemotherapy, anti-angiogenic agents, radiotherapy, novel checkpoint inhibitors, microbiome modulation, and ADCs—offer new hop

Aug 5, 2025